http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109219611-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 |
| filingDate | 2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109219611-B |
| titleOfInvention | Crystal form of dapagliflozin intermediate and preparation method thereof |
| abstract | A crystal form of an intermediate of Dapagliflozin and a preparation method thereof are disclosed, and the intermediate of Dapagliflozin (2S, 3R, 4S, 5S, 6R)-2-(4-chloro-3-(4) is specifically disclosed -Ethoxybenzyl)phenyl)-2-ethoxy-6-(methylhydroxy) tetrahydro-2H-pyran-3,4,5-triol crystal form and preparation method thereof. The advantages are that the intermediate can be highly purified to obtain a sample with a purity of more than 99.3%, which is of great significance for improving the quality of dapagliflozin, and the preparation process is simple and suitable for industrial production. |
| priorityDate | 2016-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.